LONG BEACH, Calif., Sept. 20 /PRNewswire/ -- Obagi Medical Products, Inc. (OMP), a leader in developing and marketing specialty skin health products to physicians, has initiated a multi-center, randomized-blinded clinical study evaluating wound healing and scar cosmesis in patients with superficial basal cell carcinoma (sBCC) when using their Nu-Derm® Condition and Enhance System before and after electrodessication and curettage (ED&C).
